GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HLS Therapeutics Inc (OTCPK:HLTRF) » Definitions » Intrinsic Value: Projected FCF

HLS Therapeutics (HLS Therapeutics) Intrinsic Value: Projected FCF : $6.44 (As of May. 01, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLS Therapeutics Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-01), HLS Therapeutics's Intrinsic Value: Projected FCF is $6.44. The stock price of HLS Therapeutics is $3.56. Therefore, HLS Therapeutics's Price-to-Intrinsic-Value-Projected-FCF of today is 0.6.

The historical rank and industry rank for HLS Therapeutics's Intrinsic Value: Projected FCF or its related term are showing as below:

HLTRF' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 0.16   Med: 0.71   Max: 1.84
Current: 0.55

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of HLS Therapeutics was 1.84. The lowest was 0.16. And the median was 0.71.

HLTRF's Price-to-Projected-FCF is ranked better than
91.12% of 597 companies
in the Drug Manufacturers industry
Industry Median: 1.54 vs HLTRF: 0.55

HLS Therapeutics Intrinsic Value: Projected FCF Historical Data

The historical data trend for HLS Therapeutics's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLS Therapeutics Intrinsic Value: Projected FCF Chart

HLS Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.34 7.77 7.72 7.07 8.18

HLS Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.07 5.90 6.72 6.37 8.18

Competitive Comparison of HLS Therapeutics's Intrinsic Value: Projected FCF

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics's Price-to-Projected-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Price-to-Projected-FCF falls into.



HLS Therapeutics Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get HLS Therapeutics's Free Cash Flow(6 year avg) = $13.44.

HLS Therapeutics's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*13.43536+97.697*0.8)/32.094
=6.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics  (OTCPK:HLTRF) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

HLS Therapeutics's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.56/6.4207313210682
=0.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLS Therapeutics Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of HLS Therapeutics's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


HLS Therapeutics (HLS Therapeutics) Business Description

Traded in Other Exchanges
Address
10 Carlson Court, Suite 701, Etobicoke, ON, CAN, M9W6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company products include Clozaril, Vascepa, Trinomia, and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of the world.

HLS Therapeutics (HLS Therapeutics) Headlines

From GuruFocus

Automodular Corp. (TSX:AM) - Strong Buy

By Elliot Luchansky, CFA Elliot Luchansky, CFA 03-21-2013